HRT Financial’s Cogent Biosciences COGT Stock Holding History

HRT Financial’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$387K	Buy	+10,000	New	+$350K	﹤0.01%	2891

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HRT Financial's COGT Position: Q1 2026 in Review

HRT Financial sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 81,340 shares — an estimated $2.89M sold.

HRT Financial first reported a position in COGT in Q1 2021 and held it in 4 quarters. The position peaked at $2.89M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

HRT Financial reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 81,340 Cogent Biosciences shares in Q1 2026, an estimated $2.89M.
HRT Financial first reported a position in Cogent Biosciences in Q1 2021 and held it in 4 quarters.
HRT Financial's Cogent Biosciences position peaked at $2.89M in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.